Tarceva Related Published Studies
Well-designed clinical trials related to Tarceva (Erlotinib)
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. [2008.06.03]
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. [2008.06]
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2008.05.10]
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. [2008.05]
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. [2008.02.20]
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. [2008.02]
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. [2008.01]
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. [2007.12]
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. [2007.10.20]
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. [2007.10.10]
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. [2007.07.01]
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. [2007.06]
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. [2007.05.20]
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. [2007.05]
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. [2007.04.20]
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2006.08.20]
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. [2006.05]
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. [2006.05]
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. [2006.04.24]
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. [2006.03]
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. [2005.12]
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. [2005.10]
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. [2005.09.15]
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. [2005.09.01]
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. [2005.09.01]
FDA drug approval summary: erlotinib (Tarceva) tablets. [2005.08]
Erlotinib in lung cancer - molecular and clinical predictors of outcome. [2005.07.14]
Erlotinib in previously treated non-small-cell lung cancer. [2005.07.14]
Well-designed clinical trials possibly related to Tarceva (Erlotinib)
New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. [2008.07.10]
Second-line treatment of advanced non-small cell lung cancer. [2008.04]
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? [2008.04]
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. [2006.02]
Second-line chemotherapy for non-small cell lung cancer. [2003.08]
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. [2003.05.15]
Other research related to Tarceva (Erlotinib)
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. [2008.10.20]
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2008.09.10]
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. [2008.09.10]
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. [2008.09]
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. [2008.08.15]
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. [2008.08]
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2008.07.28]
The ErbB Inhibitors Trastuzumab and Erlotinib Inhibit Growth of Vestibular Schwannoma Xenografts in Nude Mice: A Preliminary Study. [2008.07.16]
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. [2008.07.08]
An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial. [2008.07]
Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? [2008.07]
Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. [2008.07]
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. [2008.07]
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. [2008.07]
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. [2008.06.15]
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. [2008.06.15]
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? [2008.06.15]
Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. [2008.06]
Erlotinib: the first biologic in the management of pancreatic cancer. [2008.06]
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. [2008.05.20]
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. [2008.05.08]
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. [2008.05.07]
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib. [2008.02]
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. [2007.10.04]
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. [2007.10.03]
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non-Small-Cell Lung Cancer. [2007.10.01]
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. [2007.09.01]
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. [2007.08.15]
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. [2007.08.05]
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. [2007.08.01]
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. [2007.08.01]
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. [2007.08]
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. [2007.08]
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. [2007.07]
Erlotinib in cancer treatment. [2007.06]
Other possibly related research studies
The place of targeted therapy in the patient management of non-small cell lung cancer. [2007.08]
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors] [2007.09.10]
Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. [2007.07]
Developments in the treatment of non-small cell lung cancer. [2007.07]
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. [2007.07]
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?] [2007.06]
Bevacizumab in non small cell lung cancer. [2007.08.01]
Phase II trial of curcumin in patients with advanced pancreatic cancer. [2008.07.15]
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. [2008.07]
Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. [2008.06]
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis] [2008.04.19]
Targeting angiogenesis in head and neck cancer. [2008.06]
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. [2008.07.08]
Novel advances in pancreatic cancer treatment. [2008.06]
Targeted therapy in advanced non-small-cell lung cancer. [2008.06]
EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. [2008.07.08]
Present treatment and future expectations in advanced pancreatic cancer. [2008.03]
Advances in the treatment of non-small cell lung cancer. [2008.05.21]
The Development of HKI-272 and Related Compounds for the Treatment of Cancer. [2008.08]
[Non-small-cell lung cancer] [2008.05]
[Lung cancer] [2008.05.15]
Epidermal growth factor receptor-directed therapy in esophageal cancer. [2007]
Molecular targeting in pancreatic cancer. [2007.01]
Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer? [2008.06]
Delay of tympanic membrane wound healing in rats with topical application of a tyrosine kinase inhibitor. [2008.05]
Second-line and third-line chemotherapy for lung cancer: use and cost. [2008.05]
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. [2008.05]
Pancreatic cancer: From molecular signature to target therapy. [2008.04.22]
[Advances in chemotherapy for lung cancer] [2008.09]
Non-small cell lung cancer-Smokers or non-smokers, does it matter? [2008.09.11]
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? [2008.09]
Targeted therapies in head and neck cancer: past, present and future. [2008.09]
|
